oral irinotecan hydrochloride formulation VAL-413

{
  "id": "MLC-T-ONC-015696",
  "term": "oral irinotecan hydrochloride formulation VAL-413",
  "field": "Oncology and biomedicine",
  "definition": "An orally bioavailable flavored formulation composed of the hydrochloride salt form of irinotecan, a semisynthetic derivative of camptothecin, with potential antineoplastic activity. Upon oral administration of oral irinotecan HCl formulation VAL-413, irinotecan is converted to the biologically active metabolite 7-ethyl-10-hydroxy-camptothecin (SN-38) by a carboxylesterase-converting enzyme. In turn, SN-38 inhibits topoisomerase I activity by stabilizing the cleavable complex of topoisomerase I and DNA, resulting in DNA breaks. This results in an inhibition of DNA replication and an induction of apoptosis in cancer cells. VAL-413 may improve tolerability of oral irinotecan and improve compliance.",
  "synonyms": [
    "oral irinotecan HCl formulation VAL-413",
    "oral irinotecan VAL-413"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/oral-irinotecan-hydrochloride-formulation-val-413/"
}